GlobeNewsWire
18 Aug 2026, 11:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The PermeaDerm-I study showed PermeaDerm reduced product costs by 70% compared to cadaveric allograft, costing $148.70 per 1% TBSA versus $497.10. — Significant cost reduction provides a powerful economic incentive for hospital adoption, which is a primary driver for revenue growth in medical devices.
+0.80PermeaDerm demonstrated clinical outcomes comparable to allograft, with 94% of patients achieving at least 95% graft take after one week. — Clinical equivalence is a prerequisite for market penetration; proving it doesn't compromise healing removes the primary risk barrier for surgeons.
+0.60PermeaDerm reduced preparation time by 95.7% compared to allograft by eliminating tissue tracking, thawing, and meshing. — Operational efficiency and simplified workflow increase the product's attractiveness to clinicians and hospital administrators.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company announced positive clinical study results for PermeaDerm, showing comparable clinical outcomes to allografts with a 70% cost advantage.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
7h ago
